Lynn Sage Breast Cancer Symposium | Conferences

September 17, 2017

Arti Hurria, MD, director, Cancer and Aging Research Program, City of Hope, discusses challenges facing geriatric patients with breast cancer.

September 17, 2017

HER2-positive breast cancer has gone from "worst to first" because of the success of the monoclonal antibody drug trastuzumab in combination with chemotherapy.

September 17, 2017

The randomized phase IIb METRIC trial could possibly pave the way for the first FDA approval for a targeted therapy for patients with triple-negative breast cancer.

September 17, 2017

Younger women with breast cancer, which make up of around 20% of patients, present with unique disease characteristics that warrant careful consideration of potentials treatments, particularly given the potential for long-term side effects.

September 16, 2017

Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses adjuvant therapy for elderly patients with HER2-positive or triple negative breast cancer (TNBC).

September 16, 2017

Breast cancer in younger women needs a different adjuvant treatment strategy from that used in post-menopausal women, but it may not have to include suppressing ovarian function.

September 16, 2017

As the breast cancer genome continues to be unraveled, a host of new targetable alterations outside of HER2 and the estrogen receptor are beginning to emerge, providing the exciting potential for development of new therapies.

September 16, 2017

Figuring out how a certain genetic result found through multigene testing might change not only the type of intervention but its timing is the chief challenge, according to Mark Robson, MD, in a presentation at the 2017 Lynn Sage Breast Cancer Symposium.

September 15, 2017

Judith Paice, PhD, RN, Robert H. Lurie Comprehensive Cancer Center, discusses the current pain management for patients with breast cancer.

September 15, 2017

Andrew Seidman, MD, discusses the Watson for Oncology application and the potential for Watson to be a valuable partner for oncologists during the 19th Annual Lynn Sage Breast Cancer Symposium.